Clinical Trials Browser

Terminated × OTHER × Fulvestrant × Clear all

NCT03289039 2026-01-22

Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer

Phase 2 Terminated

21 enrolled 15 charts

Breast Neoplasms

NCT05082025 2026-01-09

Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations

Phase 2 Terminated

7 enrolled 10 charts

Ovarian Neoplasms, Endometrial Neoplasms

NCT06408168 2026-01-05

Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial)

Phase 2 Terminated

Carcinoma, Lobular

NCT03294694 2025-05-31

Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer

Phase 1 Terminated

BreastGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms

NCT04256941 2024-12-27

Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study

Phase 2 Terminated

4 enrolled 7 charts

Breast Neoplasms

NCT04738292 2024-05-03

Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study)

Phase 2 Terminated

11 enrolled 10 charts

Neoplasm Metastasis

NCT03322215 2024-03-08

PASIPHAE

Phase 2 Terminated

Breast Cancer Metastatic

NCT05932667 2023-12-21

DEMETER

Phase 2 Terminated

Breast Neoplasms

NCT04305236 2023-06-06

Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast Cancer

Phase 2 Terminated

1 enrolled 5 charts

Breast Neoplasms

NCT03386162 2022-11-28

SAFIR-PI3K

Phase 2 Terminated

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies

NCT02000596 2022-05-27

1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.

Phase 2 Terminated

2 enrolled 7 charts

Breast Neoplasms

NCT02269670 2022-04-05

Phase II Study of Everolimus Beyond Progression

Phase 2 Terminated

3 enrolled 4 charts

Breast Neoplasms

NCT02936206 2021-05-19

Examination of Breast Cancer Cells of Pre-menopausal and Post-menopausal Women Before and After Exposure to Tamoxifen or Fulvestrant.

Phase 1 Terminated

2 enrolled 5 charts

Breast Neoplasms

NCT00138125 2020-10-19

Fulvestrant and/or Trastuzumab as First-Line Therapy in Treating Postmenopausal Women With Stage IV Breast Cancer

Phase 2 Terminated

2 enrolled 5 charts

Breast Neoplasms

NCT00722072 2018-02-26

Sorafenib and Fulvestrant in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Aromatase Inhibitor Therapy

Phase 2 Terminated

12 enrolled 7 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT02345772 2018-02-20

Neohttp

Phase 1/2 Terminated

4 enrolled 1 chart

HER2-positive Breast Cancer

NCT00903006 2015-02-02

Trial of Fulvestrant, MK-0646, and Dasatinib for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer

Phase 1/2 Terminated

11 enrolled 6 charts

Breast Neoplasms

NCT00183963 2014-05-22

A Pilot Clinical Trial to Evaluate the Biological Activity of Fulvestrant in Breast Ductal Carcinoma in Situ (DCIS)

Phase 2 Terminated

4 enrolled 8 charts

Breast Neoplasms

NCT00206414 2013-02-05

Arimidex/Faslodex/Iressa Study: A Trial Using Arimidex, Faslodex and Iressa in Women With Breast Cancer

Phase 2 Terminated

Breast Neoplasms